PCVX
Vaxcyte, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last report1 of 8 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
No thesis.
Fund move
Fund move
Vaxcyte, Inc.
62.02
+5.31%
vs ±8.6% implied · ×0.62
shaded = implied · ▲▼ = realized
| Rank | Manager | Value | % 13F | ||
|---|---|---|---|---|---|
| 1 | FMRFMR | $1.2B | 12.06% | +26.44% | |
| 2 | Jupiter TopcoJupiter Topco | $1.0B | 10.39% | — | |
| 3 | T. Rowe Price Investment ManagementT. Rowe Price | $709.6M | 7.06% | +0.67% | |
| 4 | BlackRockBlackRockindex-like | $701.5M | 6.98% | +9.99% | |
| 5 | RA Capital ManagementRA Capital Management | $667.0M | 6.64% | 0.00% | |
| 6 | Wellington Management GroupWellington | $407.0M | 4.05% | +24.70% | |
| 7 | Vanguard Portfolio ManagementVanguard Portfolioindex-like | $383.3M | 3.81% | +5.00% | |
| 8 | Vanguard Capital ManagementVanguardindex-like | $369.0M | 3.67% | +1.31% | |
| 9 | State StreetState Streetindex-like | $311.1M | 3.10% | +20.52% | |
| 10 | Deep Track CapitalDeep Track Capital | $250.0M | 2.49% | 0.00% | |
| 11 | Geode Capital ManagementGeodeindex-like | $201.1M | 2.00% | +8.06% | |
| 12 | T. Rowe Price AssociatesT. Rowe Price | $173.8M | 1.73% | +206.12% | |
| 13 | Kynam Capital ManagementKynam | $169.9M | 1.69% | 0.00% | |
| 14 | Westfield Capital ManagementWestfield | $143.7M | 1.43% | −32.19% | |
| 15 | Caligan PartnersCaligan Partners | $127.2M | 1.27% | +6.21% | |
| 16 | Paradigm Biocapital AdvisorsParadigm Biocapital | $123.7M | 1.23% | −55.61% | |
| 17 | Susquehanna International GroupSusquehanna International | $120.8M | 1.20% | +174.29% | |
| 18 | Bellevue GroupBellevue | $114.6M | 1.14% | +65.61% | |
| 19 | D. E. ShawD. E. Shaw | $110.6M | 1.10% | −33.62% | |
| 20 | Caption ManagementCaption | $98.6M | 0.98% | +141.31% | |
| 21 | Maverick CapitalMaverick Capital | $93.8M | 0.93% | +17.09% | |
| 22 | Charles Schwab Investment ManagementCharles Schwabindex-like | $85.1M | 0.85% | +4.34% | |
| 23 | Pivotal bioVenture Partners Investment AdvisorPivotal bioVenture Partners Investment Advisor | $82.9M | 0.82% | +3.87% | |
| 24 | Eventide Asset ManagementEventide | $80.2M | 0.80% | +0.43% | |
| 25 | Goldman Sachs GroupGoldman Sachs | $80.0M | 0.80% | +5.82% |
330 managers report $10.0B of Vaxcyte on form 13F for the quarter ended Jun 30 '26. 28 of them hold 80% of it; FMR is largest at 12.06%.
Linked news
NewsExpected move
Inputs8Q avg ±5.3%·×1.38·rich
straddle ±11.1%
spot 62.03exp Nov 20ATM strike 60ATM straddle 8.07IV 67%